Compare KT & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | CRL |
|---|---|---|
| Founded | 1981 | 1947 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.6B |
| IPO Year | 2002 | 1999 |
| Metric | KT | CRL |
|---|---|---|
| Price | $18.24 | $185.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $198.27 |
| AVG Volume (30 Days) | ★ 1.9M | 716.3K |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | $0.09 | N/A |
| Revenue Next Year | $2.13 | $3.04 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $17.45 | $144.26 |
| 52 Week High | $24.58 | $228.88 |
| Indicator | KT | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 56.54 |
| Support Level | $17.69 | $161.39 |
| Resistance Level | $19.15 | $194.54 |
| Average True Range (ATR) | 0.47 | 7.25 |
| MACD | 0.12 | 0.18 |
| Stochastic Oscillator | 48.96 | 63.83 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom), KT created its own mobile operator in 1997.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.